ArticleBMC infectious diseases2026
Development and external validation of a machine learning prediction model for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children using routine blood parameters: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpstein-Barr virus (EBV) infection is a common pediatric infectious disease. Infectious mononucleosis (IM) and hemophagocytic lymphohistiocytosis (HLH), two major complications of EBV infection, share similar clinical manifestations in the early stage. While IM is typically self-limiting, HLH is life-threatening and requires immediate intervention. Early differentiation between these two conditions is crucial for clinical decision-making; however, reliable prediction models based on readily available laboratory parameters remain scarce. This study aimed to develop and validate a machine learning prediction model using routine blood parameters obtained within 24 h of hospital admission in children with confirmed acute EBV infection to distinguish EBV-associated IM (EBV-IM) from EBV-associated HLH (EBV-HLH).
methodsThis retrospective cohort study included 4,871 pediatric patients diagnosed with either EBV-IM or EBV-HLH from two campuses of Children's Hospital of Chongqing Medical University. Demographic information and initial complete blood count (CBC) parameters within 24 h of admission were collected. The cohort was divided into a model development group (Yuzhong Campus, n = 2,848; 70% for training, 30% for internal testing) and an external validation group (Liangjiang Campus, n = 2,023). Thirteen machine learning algorithms were evaluated using random search with 5-fold cross-validation for hyperparameter tuning. Shapley Additive exPlanations (SHAP) analysis was performed to interpret model predictions.
resultsEBV-HLH accounted for 12.46% (607/4,871) of the total cohort, with significantly different prevalence between the development and validation cohorts (18.29% vs. 4.25%, p < 0.001). Significant differences were observed between cohorts in age and all CBC parameters except gender (p < 0.05). The Random Forest (RF) model demonstrated optimal performance in the internal validation set (AUC = 0.993, 95% CI: 0.990-0.996). In the external validation cohort, the RF model maintained robust discriminative ability (AUC = 0.971, 95% CI: 0.949-0.992). Calibration curves indicated excellent agreement between predicted probabilities and actual risks. SHAP analysis identified WBC, PLT, LAC, and Hb as the most critical predictors of EBV-HLH. DCA demonstrated substantial clinical net benefit. A free online decision-support tool ( https://wangrj1988.shinyapps.io/EBV-HLH-IM/ ) was developed based on the RF model to facilitate real-time risk assessment.
conclusionsThe RF-based model using routine CBC parameters enables admission-based risk assessment of pediatric EBV-HLH with excellent generalizability, offering a cost-effective tool for diverse healthcare settings.
trial registrationClinical trial number: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.